Large vestibular aqueduct syndrome (LVAS/EVA — Enlarged Vestibular Aqueduct) is the most common imaging finding in pediatric sensorineural hearing loss, characterized by congenital enlargement of the vestibular aqueduct. The vestibular aqueduct is a bony canal extending between the posterior fossa dura and vestibule, through which the endolymphatic duct passes. Normal vestibular aqueduct midpoint width is <1 mm (Valvassori criterion) or <1.5 mm at operculum level (Cincinnati/Boston criterion); enlargement beyond these measurements defines large vestibular aqueduct. Bilateral involvement is seen in 60% of cases. Hearing loss is usually noticed in the prelingual period (0-3 years) and may follow progressive or fluctuating course — minor head trauma, barotrauma, or physical exertion can trigger sudden hearing loss. Strong genetic association with Pendred syndrome (SLC26A4/PDS gene mutation, thyroid organification defect + sensorineural hearing loss) — SLC26A4 mutation is detected in 30-40% of EVA patients. CT with thin-section temporal bone imaging directly measures vestibular aqueduct width; MRI with 3D CISS/FIESTA sequence demonstrates the enlarged endolymphatic sac as a T2 hyperintense tubular/cystic structure in the posterior fossa.
Age Range
0-20
Peak Age
5
Gender
Equal
Prevalence
Uncommon
Large vestibular aqueduct is a congenital inner ear developmental anomaly. In normal embryologic development, the vestibular aqueduct begins forming at gestational week 5 and approaches adult size at birth — no postnatal growth occurs. The endolymphatic duct passes through the aqueduct and reaches the endolymphatic sac (between dural leaves in posterior fossa) — the endolymphatic sac plays a critical role in endolymph homeostasis (absorption and immune function). In EVA, the aqueduct and endolymphatic sac develop larger than normal — the mechanism is not fully clear but has been shown to be associated with SLC26A4 (pendrin) gene mutation. Pendrin is an anion transporter regulating endolymph ion composition (Cl⁻/HCO₃⁻ exchange) in the inner ear — loss of function disrupts endolymphatic homeostasis → osmotic imbalance → endolymphatic space expansion. Hearing loss mechanism may be dual: (1) large aqueduct creates hypermobile endolymphatic duct → intracranial pressure fluctuations (e.g., from head trauma, cough, straining) are directly transmitted to cochlea → sensorineural damage; (2) endolymphatic homeostasis disruption affects cochlear hair cell function → progressive sensorineural hearing loss. Sudden hearing loss triggered by head trauma is also explained by 'third window phenomenon' — large aqueduct creates an additional compliance point in vestibule → sound energy escapes through this point instead of cochlea → hearing loss. CT is the best modality for measuring vestibular aqueduct bony walls; MRI evaluates endolymphatic sac size and endolymphatic duct width.
Vestibular aqueduct midpoint width >1 mm (Valvassori criterion, 1978) or >1.5 mm at operculum (distal aperture) level (Cincinnati criterion, 2007) on thin-section temporal bone CT diagnoses large vestibular aqueduct. This measurement is performed at otic capsule level in the axial plane. Pathognomonic finding confirming congenital inner ear anomaly — most common imaging finding in pediatric SNHL etiology.
Vestibular aqueduct midpoint width >1 mm (Valvassori criterion) or operculum (distal aperture) width >1.5 mm (Cincinnati criterion) on thin-section temporal bone CT (0.5-0.625 mm). Measurement is performed at otic capsule level in the axial plane — vestibular aqueduct starts from the posterolateral margin of the vestibule and courses toward posterior fossa dura. Bilateral evaluation is mandatory (60% bilateral). Degree of enlargement may correlate with hearing loss severity but is not always parallel.
Report Sentence
Vestibular aqueduct midpoint width __ mm on __ side, consistent with enlarged vestibular aqueduct (EVA); genetic evaluation for Pendred syndrome recommended.
Enlarged endolymphatic sac in the posterior fossa on MRI 3D CISS/FIESTA sequence — observed as T2 hyperintense, tubular or cystic-appearing structure. Normal endolymphatic sac is usually too small to be visualized on MRI; in EVA there is significant enlargement identified as hyperintense collection beneath posterior fossa dura. Endolymphatic duct is also imaged as enlarged — course from vestibular aqueduct to posterior fossa is followed. This finding correlates with CT bony measurement and confirms diagnosis.
Report Sentence
Enlarged endolymphatic sac in the posterior fossa on __ side on MRI 3D CISS sequence, consistent with large vestibular aqueduct syndrome.
Associated cochlear anomaly is seen in a portion of EVA cases — most commonly incomplete partition type II (IP-II, Mondini malformation): cochlea makes 1.5 turns (normal 2.5-2.75 turns), apical and middle turns are fused (modiolar deficiency). Dilated vestibule may also accompany. In presence of IP-II, cochlear implant surgery requires special attention (gusher risk — CSF leakage). In isolated EVA (without cochlear anomaly), cochlea has normal morphology. Careful evaluation of cochlear anatomy is mandatory in every EVA case.
Report Sentence
__ (normal morphology / IP-II malformation) of the cochlea observed in conjunction with large vestibular aqueduct.
Visualization of enlarged endolymphatic duct passing through vestibular aqueduct on T2-weighted images — normal endolymphatic duct is very thin on MRI and usually not visualized; in EVA, the duct is enlarged and traceable from vestibule to posterior fossa. Appears as hyperintense tubular structure. This finding correlates with bony canal enlargement on CT.
Report Sentence
Enlarged endolymphatic duct within the vestibular aqueduct on MRI T2, consistent with EVA syndrome.
Bilateral temporal bone CT comparative evaluation — since EVA is 60% bilateral, both sides should be measured separately. In cases with unilateral EVA, borderline enlargement (0.8-1.0 mm) should be monitored on the contralateral side. In bilateral cases, hearing loss affects both ears and cochlear implant planning is done separately for each side. Both vestibular aqueduct midpoint width, operculum width, cochlear morphology, and vestibule size are reported on CT.
Report Sentence
Bilateral temporal bone evaluation: right vestibular aqueduct __ mm, left vestibular aqueduct __ mm; enlarged vestibular aqueduct identified on __ side / bilaterally.
Criteria
Large vestibular aqueduct, normal cochlear morphology, normal thyroid function. SLC26A4 mutation 30-40%.
Distinct Features
Most common type. Cochlear implant suitable. Hearing loss progressive or fluctuating.
Criteria
EVA + thyroid organification defect (goiter, positive perchlorate test) + bilateral SNHL. SLC26A4 homozygous or compound heterozygous mutation.
Distinct Features
Autosomal recessive inheritance. Thyroid function tests and perchlorate test recommended. Genetic counseling mandatory.
Criteria
Large vestibular aqueduct + incomplete partition type II (cochlea 1.5 turns, modiolar deficiency).
Distinct Features
Gusher risk (CSF leakage) during cochlear implant surgery — surgeon should be warned. Preoperative MRI and CT should be evaluated together.
Distinguishing Feature
In Meniere disease vestibular aqueduct is NORMAL size (<1 mm); EVA has >1 mm enlargement. Meniere is acquired presenting in adult age while EVA is congenital diagnosed in pediatric age. In Meniere, MR hydrops protocol shows endolymphatic expansion while CT is normal; in EVA, bony anomaly is directly visible on CT.
Distinguishing Feature
Temporal bone fracture shows traumatic bone discontinuity (irregularly edged fracture line); EVA has smooth-bordered bony canal enlargement (congenital developmental). Trauma history is definitive differentiator.
Distinguishing Feature
Middle ear effusion shows opacification in middle ear and mastoid; EVA pathology is in inner ear (vestibular aqueduct enlargement) with normal middle ear. Two different anatomic compartments.
Urgency
routineManagement
conservativeBiopsy
Not NeededFollow-up
6-monthEVA is the most common imaging finding in pediatric SNHL and early diagnosis is critical for hearing rehabilitation. Management: (1) Hearing rehabilitation — hearing aids (mild-moderate loss) or cochlear implant (severe loss); cochlear implant gives very successful results in EVA patients; (2) Hearing preservation — contact sports avoidance, head trauma protection (can trigger sudden hearing loss), barotrauma avoidance (diving, flying); (3) Pendred syndrome screening — thyroid function tests, perchlorate test, SLC26A4 genetic testing; (4) Genetic counseling — autosomal recessive inheritance (25% risk if both parents carriers); (5) Follow-up — serial audiometry (6-12 month intervals) to monitor hearing loss progression. If IP-II accompanies, surgeon should be informed about gusher risk during cochlear implant surgery.
LVAS/EVA is the most common imaging finding in pediatric SNHL and early diagnosis is critical for hearing rehabilitation. Hearing loss may be progressive or fluctuating; minor head trauma can trigger sudden hearing loss. Pendred syndrome workup (thyroid function tests, perchlorate test, SLC26A4 genetic testing) is recommended. Cochlear implantation is an effective treatment option in appropriate patients. Contact sports avoidance is advised.